Pharmaceutical giant Eli Lilly is reportedly nearing a major acquisition deal with Kelonia Therapeutics valued at more than $2 billion, according to a Sunday report from the Wall Street Journal.
The negotiations are said to be in their final stages, though independent confirmation of the potential purchase agreement has not yet been obtained.
The reported acquisition would represent a significant investment by Eli Lilly as the company continues to expand its therapeutic portfolio and market presence.
